A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus.
A simplified hepatitis A virus (HAV) antigen-reduction neutralization assay (HAVARNA) was developed to permit the measurement of biologically active antibodies in recipients of candidate HAV vaccines. Degrees of neutralization were measured from the reduction in the amount of HAV antigen synthesized by 7-10 days after infection of MRC-5 (fetal human diploid lung) cell cultures. Sera producing a greater than or equal to 50% reduction in viral infectivity were scored as neutralizing. The assay was applied to demonstrate serum HAV neutralizing activity in 10 of 10 and 9 of 10 recipients of 10(7) and 10(6) TCID50 doses, respectively, of the Merck CR326F (F' variant) live attenuated vaccine. The dilution end points of selected sera ranged from 1:10 to 1:640. The dilution end point of the World Health Organization reference globulin no. 1 was 1:530,000 (0.2 mlU/ml of HAV antibody). The HAVARNA provided a rapid, sensitive, and reproducible means to measure neutralizing antibodies to HAV.
Krah
D L
DL
Department of Cellular and Molecular Biology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Amin
R D
RD
Nalin
D R
DR
Provost
P J
PJ
D000328:Adult; D006508:Hepatitis Antibodies / Q000032:analysis*; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests / Q000379:methods
D006508:Hepatitis Antibodies